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Abstract
Background: Medication errors occur frequently at points of transition in care. The key problems causing these
medication errors are: incomplete and inappropriate medication reconciliation at hospital discharge (partly arising
from inadequate medication reconciliation at admission), insufficient patient information (especially within a
multicultural patient population) and insufficient communication to the next health care provider. Whether
interventions aimed at the combination of these aspects indeed result in less discontinuity and associated harm is
uncertain. Therefore the main objective of this study is to determine the effect of the COACH program (Continuity
Of Appropriate pharmacotherapy, patient Counselling and information transfer in Healthcare) on readmission rates
in patients discharged from the internal medicine department.
Methods/Design: An experimental study is performed at the internal medicine ward of a general teaching hospital in
Amsterdam, which serves a multicultural population. In this study the effects of the COACH program is compared with
usual care using a pre-post study design. All patients being admitted with at least one prescribed drug intended for
chronic use are included in the study unless they meet one of the following exclusion criteria: no informed consent, no
medication intended for chronic use prescribed at discharge, death, transfer to another ward or hospital, discharge
within 24 hours or out of office hours, discharge to a nursing home and no possibility to counsel the patient.
The intervention consists of medication reconciliation, patient counselling and communication between the hospi-
tal and primary care healthcare providers.
The following outcomes are measured: the primary outcome readmissions within six months after discharge
and the secondary outcomes number of interventions, adherence, patient’s attitude towards medicines, patient’s
satisfaction with medication information, costs, quality of life and finally satisfaction of general practitioners
and community pharmacists.
Interrupted time series analysis is used for data-analysis of the primary outcome. Descriptive statistics is performed
for the secondary outcomes. An economic evaluation is performed according to the intention-to-treat principle.
Discussion: This study will be able to evaluate the clinical and cost impact of a comprehensive program on
continuity of care and associated patient safety.
Trial registration: Dutch trial register: NTR1519
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Background
Medication errors are the most common type of errors
affecting patient safety, occurring most frequently at
points of transition in care [1-3]. There are three key
problems causing these medication errors at hospital
admission and discharge. The first problem is incom-
plete and inappropriate medication lists. This problem
starts at hospital admission for example due to recall
bias of the patient, incomplete medication records (e.g.
absence of over-the-counter drugs) and inappropriately
prescribed drugs (e.g. indication of pre-hospital pre-
scribed drugs not evaluated) [4]. These admission medi-
cation errors can carry over to the discharge medication
and new medication errors can occur for example when
hospital physicians forget to restart temporarily discon-
tinued medication or do not evaluate the appropriate-
ness of discharge medication [5,6].
The second problem is insufficient patient information.
While receiving care in hospital patients often get help
with the preparing and administering of their medication
by hospital staff. However, following hospital discharge
patients are abruptly expected to manage their medica-
tion themselves, with little support or preparation [3].
The last problem regards insufficient communication to
the next health care provider. Discharge letters and dis-
charge prescriptions generally do not contain the entire
pharmacotherapy [7,8]. This incompleteness could lead to
confusion about whether the medication which is not
listed is discontinued or just not mentioned. Both the
general practitioner and community pharmacy are not
informed on reasons for changes in the pharmacotherapy
leading to confusion whether these changes should be
maintained or were temporal [9,10].
Evidence exists on the effect of discharge medication
related interventions on reducing adverse events, redu-
cing the readmission rate and improving adherence
[5,11-15]. However, some studies showed no effect and
Holland et al. reported contradictory results on readmis-
sion rates [16-18]. Most studies have not combined inter-
vention types to solve the problems as described above.
For example, medication reconciliation is often per-
formed with the use of medication records without active
involvement of patients, or in case patients are involved,
patients who are unable to speak the native language of
the study location are excluded [12,16,19-21]. In contrary,
some studies are so comprehensive that it is expected
that most hospitals cannot implement such time consum-
ing interventions (e.g. one study reports 2 hours per
patient) [21-23]. Furthermore, in general the intervention
is performed (partly) by pharmacists making the interven-
tion expensive [5,11-19,21-23]. It is unknown what the
effect is of discharge medication related interventions
when they are performed by healthcare providers with a
lower level of education.
Therefore, the COACH (Continuity Of Appropriate
pharmacotherapy, patient Counselling and information
transfer in Healthcare) program is designed to improve
continuity of care by combining interventions, including
non-native patients and using pharmaceutical consul-
tants (i.e. pharmacy technicians who have followed addi-
tional training) to perform the intervention. The
intervention consists of medication reconciliation at dis-
charge (in addition to medication reconciliation at
admission to prevent medication errors from carrying
over to the discharge medication), patient counselling at
discharge and communication of medication informa-
tion to the next healthcare providers.
At present it is unknown whether such an interven-
tion program indeed can lead to less discontinuity and
associated patient harm. Therefore, the main objective
of this study is to determine the effect of the COACH
program on readmissions after six months in a multicul-
tural population from the internal medicine department.
Methods/Design
Design
A prospective experimental study with a before-after
design is performed at the St. Lucas Andreas Hospital in
the Netherlands, a 550-bed general teaching hospital
serving a multicultural population. The study is carried
out from June 2009 through Januari 2011. The effects
between a usual care group and an intervention group
(pre- and post-intervention measurement design) are
compared. First, patients are included during five
months in the usual care group (pre-intervention phase
with six months follow-up). Second, the intervention is
implemented in the study ward (implementation phase
of 3 months). Finally, patients are included during five
months in the intervention group (post-intervention
phase with six month follow-up, see figure 1 for flow-
chart and measurements).
Study population
The study is performed at the internal medicine ward.
All patients admitted with at least one prescribed drug
intended for chronic use are invited to participate.
Exclusion criteria are: no informed consent, no medica-
tion intended for chronic use prescribed at discharge,
death, transfer to another ward or hospital, discharge
within 24 hours or out of office hours, discharge to a
nursing home (as patients do not administer their own
medication) and patients who cannot be counselled (as
stated by the resident due to physical/mental con-
straints, being critically ill or due to language restric-
tions without relatives or healthcare personnel to
translate, i.e. languages other than Dutch, Turkish, Eng-
lish and Arabic/Berber). Only the patient’s first hospital
admission is included in the study period (readmissions
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are the main outcome measure). The St. Lucas Andreas
Hospital institutional review board has stated that this
study is exempt from review by the institutional review
board as the Dutch legislation does not request this for
studies that do not affect the patient’s integrity. In this
study the burden was considered minimal for the
patient and therefore the medical ethics committee
waived the review. The burden is minimal as the patient
will receive counselling about his discharge medication
in the intervention group. This should be usual practice
as the hospital has a legal obligation to inform patients.
The patients is also asked to fill in questionnaires and
cost diaries. This is expected to take 60 minutes of the
patient’s time. To respect the wish of a patient to parti-
cipate in a study we decided to ask the patients for an
informed consent to obtain information from their gen-
eral practitioner on readmission rates and for filling in
the questionnaires/cost diaries. Patient data are sampled
and stored in accordance with privacy regulations.
Study procedures
Usual care
Medication reconciliation on admission At hospital
admission residents mostly use the information pro-
vided by patients (or relatives) or previous hospital
records (e.g. discharge letters, patient charts) to exam-
ine the pre-admission medication. However, medica-
tion reconciliation is not structurally performed by the
resident. Residents can consult the medication records
of the community pharmacy through a link in the hos-
pital’s Computerized Physician Order Entry (CPOE)
system for patients that are within the catchment area
of the hospital. If a community pharmacy is not
connected to the hospital’s CPOE, the resident can
request the hospital pharmacy to obtain a faxed medi-
cation list from the community pharmacist. The resi-
dent registers the admission prescriptions in the
hospital’s CPOE where after the prescriptions are
checked during hospital admission by the clinical phar-
macist on dosages, double medication, drug-drug inter-
actions and contra-indications.
At present information on allergies is not structurally
provided to the clinical pharmacist making medication
surveillance on allergies impossible.
Medication reconciliation at discharge The resident
prints a medication list from the hospital’s CPOE. On
this medication list the resident can adjust the medica-
tion and he then indicates which medication should be
dispensed by the community pharmacy. The medication
list is sent to the hospital pharmacy. The pharmacy
technician screens the list for obvious errors (e.g. dose
not provided) but no structured medication reconcilia-
tion is performed.
Patient counselling at discharge To support the
patient counselling a medication list is written down by
the resident using the information in the hospital’s
CPOE. At present, residents and nurses are involved in
patient instructions on pharmacotherapy. For both pro-
fessionals this aspect is only a relatively small part of a
large amount of tasks, making the time to be spent on
medication related patient instructions rather limited
or the patient counselling is not performed at all. Also,
the knowledge necessary for providing adequate
instructions is often insufficient in residents (inexper-
ienced) and nurses (training provides little knowledge
on drugs).
Figure 1 Study flow of the COACH program. t = 0,1,3,6; at hospital discharge, one month, three months, six months after hospital discharge.
GP = general practitioner. CP = community pharmacist.
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Communication of discharge medication After screen-
ing of the medication list by the pharmacy technician at
discharge, the discharge prescriptions are sent to the
community pharmacy. The community pharmacist is
mostly informed on medication which should be dis-
pensed. The reasons for changes in therapy or clinical
information such as allergies are not provided.
The communication to the general practitioner takes
place through the discharge letter in which the medica-
tion is typed by the resident. The medication list in the
discharge letter is generally incomplete and provides lit-
tle or no information on changes in the pharmacother-
apy and the reasons for these changes.
COACH intervention program
The COACH intervention program is carried out by a
team of pharmaceutical consultants with clinical pharma-
cists as supervisors. Pharmaceutical consultants are phar-
macy technicians who have followed an additional three
year bachelor program which is focused on pharmaceutical
patient care. They are specifically trained in pharmacother-
apy and communication with patients. In contrast to
nurses and residents, they can dedicate more time to the
patient, as this job is their main task. Because of their lower
level of education, when compared to pharmacists who
have had a 6 year university training, salary expenditures
for pharmaceutical consultants are lower, which is why
they are used besides a supervising pharmacist.
As 30-40% of the patient population in the St. Lucas
Andreas hospital is originating from foreign countries
(migrants, mostly Turkish and Moroccan) information
leaflets and questionnaires are available in Dutch, Turk-
ish, Arabic and English. Arabic is the written language
of Morocco, but Moroccan immigrants in the Nether-
lands often use the Berber language (a non-written lan-
guage) and are unable to read Arabic. In those cases
relatives or healthcare personnel are asked to translate
the information leaflets.
The COACH program consists of four main processes
that are subdivided in subprocesses (see figure 2).
Although the program focuses on discharge, a small
part of the intervention is carried out on admission to
prevent admission medication errors to carry over to
the discharge medication.
Obtaining basic information and medication
reconciliation on admission
After the pharmaceutical consultant gets informed con-
sent from the patient at admission the consultant asks
the patient about possible allergies. If any are mentioned
the pharmaceutical consultant registers the allergy in the
CPOE for medication surveillance purposes. Further-
more, the language spoken by the patient is checked. If a
Figure 2 Implementation of the COACH program. MR = medication reconciliation. PC = patient counselling following the steps for
medication reconciliation. DRPs = drug related problems.
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patient cannot speak or understand Dutch a family
member or friend is asked to be present and translate or
a specific health care worker speaking the native language
of the patient is added to the team. Finally, the pharma-
ceutical consultant asks some additional basic informa-
tion (see figure 2 and table 1, step 1). Hereafter an
information leaflet is given to the patient. This leaflet
informs the patient further about the project and moti-
vates the patients to ask questions about medication
during patient counselling at discharge.
After the resident registers the admission prescription
in the hospital’s CPOE the pharmaceutical consultant
verifies these prescriptions using community pharmacy
records without counselling the patient (due to time
constraints and because the resident already counsels
the patient following routine care). All discrepancies
("on paper”) with the pre-admission medication, known
allergies and possible drug-related problems are
communicated to the resident with a standardized form
(see figure 2 and table 1, step 2). The resident can adjust
the prescriptions if necessary.
Medication reconciliation at discharge
At discharge medication reconciliation is performed
again using a protocol which contains the steps for
Table 1 Protocols used for the steps shown in figure 2
Steps Protocols used consists of
1 Questions asked: allergies, presence of relative during patient counselling at discharge, marital status, birth country patient and parents,
education, readmission rate previous six months
2 Check:
- Matching of medication at admission with pre-admission medication regarding drug, dose, route and frequency
3 Check:
- Matching of medication at discharge with pre-admission medication regarding drug, dose, route and frequency
- Whether temporally discontinued medication and substituted medication (due to hospital formulary policy) should be resumed
4 Check:
- Continuing need: discontinue not indicated (temporally prescribed) medication
- Consider right dose (e.g. for geriatric patient), simplify drug regimen (e.g. modified release product in stead of plain drug), duration of
therapy (e.g. antibiotic prescribed too long, gradually reduce prednisolone)
- Laboratory values: international normalized ratio, glomerular filtration rate, glucose, sodium and potassium blood levels to adjust
medication if necessary.
- Identify suboptimal treatment (e.g. laxative with opioid, gastroprotection with NSAID and risk factors, rescue medication with inhaled
corticosteroid, bisfosfonate with long-term prednisolone, isordil with ACS, statin with diabetes mellitus type II)
- Drug-drug interactions (pharmacokinetic and pharmacodynamic) and contra-indications (e.g. NSAID with heart failure, COX-2 inhibitor with
ischemic heart disease)
- Consider cost (e.g. brand to generic drug)
- Consider monitoring (e.g. therapeutic drug monitoring, electrolytes, creatin)
5 Check:
- Appropriateness of new medication
- Documentation of (reasons for) changes between discharge prescriptions and pre-admission medications
7 Check:
- How medication is used by the patient and at what time point.
- Continuing need: discontinue not indicated (temporally prescribed) medication or restart medication if patient does not agree with
discontinuation (e.g. patient still has pain)
- Other medication usage (e.g. over-the-counter medication or herbals) to evaluate whether there are contra-indications or interactions with
the medication prescribed at discharge
8 Check:
- Practical problems with medication use: check whether patient is capable of using his medication (e.g. big tablets, type of inhalator)
- Occurrence of adverse drug reactions: check whether these could be prevented or minimized
- Forgetting of medication: check whether patient is compliant and what the possible reasons are for non-adherence. Problems with
adherence are further explored and possible tools, such as pill boxes, are discussed.
9 Check:
- Understanding of new prescribed medication
- Knowledge of side effects (e.g. bloody or black tarry stools with anticoagulants to recognize bleeding, risk of fracture and prednisolone,
increase of blood sugar and prednisolone, rapid heart beats and bronchodilators, sore throat and inhalalation corticosteriods to rinse mouth,
stomach pain and NSAID, headache and nitrates/beta-blockers, muscle pain and lipid-lowering medicines, orthostatic hypotension and
antihypertensives, diarrhoea and antibiotics, risk of falls/drowsiness and hypnotics, muscle weakness and paraesthesia to recognize low/high
potassium)
- Written information need: give patient information leaflet for new prescribed medication
- Whether there are questions
- Which medication the patient still has in stock at home and which medication should be dispensed.
11 Register on the medication discharge overview: changes in medication and reasons, possible drug-related problems and follow-up
procedures (e.g. therapeutic drug monitoring). This information is automatically registered on the medication summary for the patient also.
ACS = Acute coronary syndrome
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medication reconciliation (see figure 2 and table 1, step
3-5) [24]. First in the verification step the presence of
discrepancies with the pre-admission medication is
examined again by using the medication history of the
community pharmacy. Second, in the clarification step
the appropriateness of the pharmacotherapy is checked
and the pharmacotherapy is evaluated. Also the interna-
tional normalized ratio, glomerular filtration rate, glu-
cose, sodium and potassium blood levels are checked to
adjust medication if necessary. In the third step the
newly initiated medication is evaluated to ensure all
changes are intentional and changes in the pharma-
cotherapy are documented. Finally, the results of all
steps are discussed with the resident and the prescrip-
tions are adjusted if necessary.
Patient counselling at discharge
To support patient counselling a comprehensive medica-
tion summary for the patient is developed (see figure 3
and 4). This double sided medication summary is printed
from the hospital’s CPOE. One side contains contact
information of the hospital, advices on side effects and
advices on patient involvement in healthcare (see figure
3). This information is based on several literature reports
[25-27]. The other side contains patient data, clinical
information (e.g. allergies, contra-indications), hospital
physician information, start and stop date for medication,
medication name (brand and generic for the patient to
recognize his medication), dose information and advices,
reason for changes in pharmacotherapy (bold text) and a
daily time table (see figure 4).
After the medication reconciliation has been per-
formed and discussed with the resident, the pharma-
ceutical consultant counsels the patient and/or his
family. The patient counselling is also carried out by
following the steps for medication reconciliation (see
figure 2 and table 1, step 7-9). First, details of all medi-
cations are confirmed in the verification step by using
the medication summary. The pharmaceutical consul-
tant asks the patient how medication is used (to see
whether the use is correct), whether medication is not
in use anymore or whether additional medication
is used. Second, the clarification step is performed
through checking whether improvements can be made
on safety and quality of pharmacotherapy and
explaining or answering questions. Third, in the recon-
ciliation step new medication is discussed to evaluate
whether the patient understands why this medication
is prescribed.
The counselling is not only aimed at gathering infor-
mation about the actual medication usage but also at
educating the patient about changes in the pharma-
cotherapy and involving the patient in the optimisation
of the medication usage. If relevant, special attention is
paid to subjects relevant for specific patient populations,
such as use of medication during fasting. The counsel-
ling is inside the hospital, at bedside or in a separate
room if preferred by the patient.
The results of patient counselling are discussed with
the resident and the prescriptions can be adjusted if
necessary. This results in the final discharge medication.
Communication of discharge medication
To support the communication of discharge medica-
tion a discharge medication overview is developed
(see figure 5). This discharge medication overview is
printed from the hospital’s CPOE and contains contact
information of the hospital, patient data, clinical infor-
mation (e.g. allergies, contra-indications), hospital
physician information, start and stop date of medica-
tion, generic medication name, dose information,
reasons for changes in pharmacotherapy, drug-related
problems, follow-up actions, the amount of medication
that has to be dispensed by the community pharmacy,
information on tools for adherence and preference of
patient to have his medication delivered at home by
the pharmacy.
The discharge medication overview is faxed to the
community pharmacy before discharge. The overview is
also send to the general practitioner by e-mail.
Study endpoints and data collection
The primary outcome of this study is the readmission
rate within six months after discharge. In addition, sev-
eral secondary outcome measures with respect to medi-
cation safety are measured and analysed: number of
interventions, adherence, patient’s attitude towards med-
icines and satisfaction with medication information,
costs-effectiveness of the intervention, quality of life and
satisfaction of general practitioners and community
pharmacists.
For collection of outcome parameters, hospital
patient records, primary care patient records and
validated questionnaires/forms are used. Data are
collected prospectively during the pre-intervention and
post-intervention period, and in the period up to six
months after discharge. The following parameters are
registered:
➢ readmission within six months after discharge (pri-
mary outcome): the hospital information system is used
to register readmissions of the patients in the same hos-
pital. The patient’s general practitioner is asked for read-
missions in other hospitals.
➢ patient characteristics: these are extracted from the
medical records of the hospital information system
including gender, age, morbidities, length of stay.
➢ interventions performed in the discharge interven-
tion process: prescribed medication at discharge is
extracted from the initial medication order forms in the
hospital’s CPOE. All changes (due to correction of
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Figure 3 Medication summary for the patient (reverse side). The medication summary is folded to a A6-format.
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medication errors or optimisation of pharmacotherapy)
in these initial medication orders are registered by the
research pharmacist. Also all explanations provided to
the patient during patient counselling are registered as
an intervention. Interventions performed in the admis-
sion process are not documented for this study. The
interventions at discharge are classified according to our
previously described classification system [28].
➢ patients are asked to fill out a questionnaire about
their adherence to drug treatment (MARS; Medication
Adherence Rating Scale) [29], satisfaction with informa-
tion about medicines (SIMS) [30] and their attitude
towards drugs (BMQ; Beliefs about Medicines Question-
naire) [31]. After the discharge counselling the patient is
given a questionnaire (MARS, BMQ, SIMS) which is
filled out before discharge. After one month a second
short questionnaire (MARS, BMQ) is sent to evaluate
whether adherence and the beliefs about medication
have changed after one month.
➢ satisfaction of GPs and community pharmacies: a
questionnaire is sent to the patient’s general practitioner
and community pharmacist within two days of discharge
to evaluate their satisfaction with the information on the
patient’s discharge medication.
➢ cost-effectiveness estimate and quality of life: the
aim of the economic evaluation is to determine and
compare the total costs of the COACH program com-
pared with usual care in patients and to relate these
costs to the effects of these two approaches. The phar-
macist and counsellors register the time and material
spent on the intervention.
All patients are asked to collect data about healthcare
utilisation and quality of life (EuroQol) through monthly
sent cost diaries (up to three months) [32]. These cost
diaries have been proven to be valid and reliable and
have previously been used in economic evaluations in pri-
mary care that included patients of Moroccan and Turk-
ish origin [33-38]. The cost diaries are translated and
supplied in the patient’s preferred language. Healthcare
costs, patient and family costs, and production losses are
included. All costs of healthcare are assessed as it is hard
to distinguish which costs are related to medication use.
Healthcare costs include the costs of visits to the general
practitioner, medical specialist, hospitalisations and medi-
cation costs. Patient and family costs include costs of
over the counter medication, informal care and alterna-
tive treatments. Costs of productivity losses due to the
absence from paid and unpaid work are also estimated.
Figure 4 Medication summary for the patient (front side). The administration scheme is filled in with the help of the patient. In bold text
the reasons for changes in the pharmacotherapy, drug related problems and follow-up actions can be specified.
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Sample size
The primary outcome measure is the readmission rate
within six months after discharge. The effects of pre-
vious studies into pharmacist pre-discharge medication
reconciliation combined with patient counselling on the
reduction of the frequency of readmission vary widely
[12,13,15,21-23]. Four studies report an absolute
decreased readmission rate of 13-30% and two studies
report 5-9% (median 15%). Based on a conservative
interpretation of these studies, it is estimated that the
intervention reduces the proportion of readmitted
patients in a comparable population with 10% from 25%
in the usual care group to 15% in the intervention
group. However, the populations in these studies are
not fully comparable to our population: previous studies
were limited to elderly patients and our study also
includes younger patients. We expect a lower proportion
of readmitted patients in both the usual care as the
intervention group, because hospital admissions related
to medication are less frequent in younger patients com-
pared to elderly, and this probably also applies to hospi-
tal readmissions after discharge. As there are no exact
numbers for the proportion of readmissions in younger
patients, we use the most conservative approach that no
patients younger than 65 will be readmitted. At the
internal ward in our hospital, the proportion of patients
younger than 65 years being discharged is about 20%.
Given the assumption that no younger patients are read-
mitted, the proportion of readmitted patients is 20%
lower in both groups. The estimated proportions of
readmitted patients are 20% in the usual care and 12%
in the intervention group. With these proportions, the
expected reduction of readmitted patients is 8%. With a
type 1 error of 0.05, a power of 80%, and equal sample
sizes, a total of 360 patients per group is needed.
At the Department of Internal Medicine 150-180
patients are being discharged each month. With an esti-
mated proportion of 40% of the patients being excluded
due to the exclusion criteria and considering loss to fol-
low-up, it is expected that the period to evaluate usual
care and the intervention will take about five months
for each group.
Subjects can leave the study at any time for any reason
if they wish to do so without any consequences. The
Figure 5 Discharge medication overview for community pharmacist and general practitioner. In the remarks section reasons for changes
in the pharmacotherapy, drug-related problems and follow-up actions can be specified. This overview is faxed to the community pharmacist. If
Vitamin K antagonists are prescribed the text “Please inform anticoagulation clinic” is printed to request the community pharmacy to inform the
anticoagulation clinic about the final discharge prescriptions. The information in the red blocks is mailed to the general practitioner.
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number of excluded patients and reasons for exclusion
are registered. The same applies to patients who drop out
of the study after inclusion. If the agreement with
informed consent is not withdrawn, data that have been
collected until drop out are included in the analysis.
Data analysis
Patients from the intervention and control group are
compared for all baseline characteristics using relative
risks with 95% confidence intervals. For the primary
endpoint (readmissions) interrupted time series analysis
is used for data-analysis. Baseline data are collected over
5 months (with 3 separate measurements), as will be the
post-intervention data. The study design thus meets the
criteria for a robust interrupted time series analysis, that
is 3 data-points pre- and post-intervention, each consist-
ing of at least 30 patients [39]. Subgroup analysis is per-
formed for ethnicity and the results are corrected for
potential confounders such as gender, age and underly-
ing disease. Descriptive statistics is performed for the
secondary outcomes (interventions registered, adher-
ence, patient’s attitude towards medicines, satisfaction
with medication information and satisfaction of the gen-
eral practitioner and community pharmacist). Continu-
ous measures are summarized using means and
standard deviations and categorical measures are sum-
marized using percentages.
The economic evaluation is performed according to the
intention-to-treat principle and from a societal perspec-
tive. Bootstrapping is used for pair-wise comparison of
the mean differences in total costs between treatment
groups. Confidence intervals are obtained by bias cor-
rected and accelerated bootstrapping, using 5000 replica-
tions. Both a cost-effectiveness and cost-utility analysis is
performed. Cost-effectiveness ratio’s are calculated by
dividing the difference between the mean costs of the
two treatment groups by the difference in the mean
effects of the two treatment groups. Cost-utility is based
on the EuroQol and expressed in costs per quality
adjusted life year. Cost-effectiveness and cost-utility
ratios are estimated using boot-strapping techniques and
graphically presented on cost-effectiveness and cost uti-
lity planes. Acceptability curves are also presented. Sensi-
tivity analysis on the most important cost drivers are
performed in order to assess the robustness of the results.
Discussion
Several randomized controlled trials have been per-
formed which dealt with continuity of care and
described one or more interventions which are also con-
ducted in our study (medication reconciliation, patient
counselling and transfer of information on medication
to primary care) [5,12-15]. Contrary to these studies we
regarded a randomized design as not feasible, because
previous experiences with pilot projects have shown that
the COACH program contaminates usual care as resi-
dents and other healthcare providers learn from the
COACH program. The program therefore influences
prescribing behaviour and the organisation of care.
Therefore, we have chosen for an observational before-
after design including interrupted time series as the pre-
ferred alternative [39].
We expect this study to have several strengths. First,
we have gained experience due to previous pilot projects
and have been able to optimize the process such as
accurate medication reconciliation and more structured
patient counselling. We have also optimized documents
such as the medication summary for the patient and the
medication overview for the general practitioner and
community pharmacist. Second, due to previous experi-
ences pharmaceutical consultants are trained in recog-
nizing drug-related problems. Third, in contrast to other
studies we are also conducting a cost-effectiveness
assessment. Finally, in this study we will estimate the
effect of the COACH program in a multicultural popu-
lation which will provide more insight in the effect of
discharge counseling in ethnic minority patients.
This study also has some limitations. First, selection
bias is possible as especially ethnic minority groups
might not want to cooperate. This could also lead to
failure to reach the recruitment target and hence could
reduce the study’s statistical power to detect differences
in the primary outcome. Second, previous studies have
shown mixed results. It is unknown which interventions
are effective and how long the follow-up period should
be. Nevertheless, we believe the comprehensive COACH
program will be able to show effect on patient safety
related outcomes. Finally, as it concerns a monocenter
study this may limit generalisability.
Studies generally have shown the effect of discharge
medication related interventions on reducing adverse
events, medication errors and drug-related problems
[5,12-15]. This study however, will be able to evaluate
the clinical and cost impact of a comprehensive pro-
gram on continuity of care. The possible impact of the
COACH program on hospital readmissions will provide
insight in the quality of care. The findings from this
study will provide information of interest to many stake-
holders, including patients, health care managers, policy
makers and health care professionals.
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